Cargando…

Patient and parent preferences for characteristics of prophylactic treatment in hemophilia

INTRODUCTION: New longer-acting factor products will potentially allow for less frequent infusion in prophylactic treatment of hemophilia. However, the role of administration frequency relative to other treatment attributes in determining preferences for prophylactic hemophilia treatment regimens is...

Descripción completa

Detalles Bibliográficos
Autores principales: Furlan, Roberto, Krishnan, Sangeeta, Vietri, Jeffrey
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4664548/
https://www.ncbi.nlm.nih.gov/pubmed/26648701
http://dx.doi.org/10.2147/PPA.S92520
_version_ 1782403442754453504
author Furlan, Roberto
Krishnan, Sangeeta
Vietri, Jeffrey
author_facet Furlan, Roberto
Krishnan, Sangeeta
Vietri, Jeffrey
author_sort Furlan, Roberto
collection PubMed
description INTRODUCTION: New longer-acting factor products will potentially allow for less frequent infusion in prophylactic treatment of hemophilia. However, the role of administration frequency relative to other treatment attributes in determining preferences for prophylactic hemophilia treatment regimens is not well understood. AIM: To identify the relative importance of frequency of administration, efficacy, and other treatment characteristics among candidates for prophylactic treatment for hemophilia A and B. METHOD: An Internet survey was conducted among hemophilia patients and the parents of pediatric hemophilia patients in Australia, Canada, and the US. A monadic conjoint task was included in the survey, which varied frequency of administration (three, two, or one time per week for hemophilia A; twice weekly, weekly, or biweekly for hemophilia B), efficacy (no bleeding or breakthrough bleeding once every 4 months, 6 months, or 12 months), diluent volume (3 mL vs 2.5 mL for hemophilia A; 5 mL vs 3 mL for hemophilia B), vials per infusion (2 vs 1), reconstitution device (assembly required vs not), and manufacturer (established in hemophilia vs not). Respondents were asked their likelihood to switch from their current regimen to the presented treatment. Respondents were told to assume that other aspects of treatment, such as risk of inhibitor development, cost, and method of distribution, would remain the same. RESULTS: A total of 89 patients and/or parents of children with hemophilia A participated; another 32 were included in the exercise for hemophilia B. Relative importance was 47%, 24%, and 18% for frequency of administration, efficacy, and manufacturer, respectively, in hemophilia A; analogous values were 48%, 26%, and 21% in hemophilia B. The remaining attributes had little impact on preferences. CONCLUSION: Patients who are candidates for prophylaxis and their caregivers indicate a preference for reduced frequency of administration and high efficacy, but preferences were more sensitive to administration frequency than small changes in annual bleeding rate.
format Online
Article
Text
id pubmed-4664548
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-46645482015-12-08 Patient and parent preferences for characteristics of prophylactic treatment in hemophilia Furlan, Roberto Krishnan, Sangeeta Vietri, Jeffrey Patient Prefer Adherence Original Research INTRODUCTION: New longer-acting factor products will potentially allow for less frequent infusion in prophylactic treatment of hemophilia. However, the role of administration frequency relative to other treatment attributes in determining preferences for prophylactic hemophilia treatment regimens is not well understood. AIM: To identify the relative importance of frequency of administration, efficacy, and other treatment characteristics among candidates for prophylactic treatment for hemophilia A and B. METHOD: An Internet survey was conducted among hemophilia patients and the parents of pediatric hemophilia patients in Australia, Canada, and the US. A monadic conjoint task was included in the survey, which varied frequency of administration (three, two, or one time per week for hemophilia A; twice weekly, weekly, or biweekly for hemophilia B), efficacy (no bleeding or breakthrough bleeding once every 4 months, 6 months, or 12 months), diluent volume (3 mL vs 2.5 mL for hemophilia A; 5 mL vs 3 mL for hemophilia B), vials per infusion (2 vs 1), reconstitution device (assembly required vs not), and manufacturer (established in hemophilia vs not). Respondents were asked their likelihood to switch from their current regimen to the presented treatment. Respondents were told to assume that other aspects of treatment, such as risk of inhibitor development, cost, and method of distribution, would remain the same. RESULTS: A total of 89 patients and/or parents of children with hemophilia A participated; another 32 were included in the exercise for hemophilia B. Relative importance was 47%, 24%, and 18% for frequency of administration, efficacy, and manufacturer, respectively, in hemophilia A; analogous values were 48%, 26%, and 21% in hemophilia B. The remaining attributes had little impact on preferences. CONCLUSION: Patients who are candidates for prophylaxis and their caregivers indicate a preference for reduced frequency of administration and high efficacy, but preferences were more sensitive to administration frequency than small changes in annual bleeding rate. Dove Medical Press 2015-11-23 /pmc/articles/PMC4664548/ /pubmed/26648701 http://dx.doi.org/10.2147/PPA.S92520 Text en © 2015 Furlan et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Furlan, Roberto
Krishnan, Sangeeta
Vietri, Jeffrey
Patient and parent preferences for characteristics of prophylactic treatment in hemophilia
title Patient and parent preferences for characteristics of prophylactic treatment in hemophilia
title_full Patient and parent preferences for characteristics of prophylactic treatment in hemophilia
title_fullStr Patient and parent preferences for characteristics of prophylactic treatment in hemophilia
title_full_unstemmed Patient and parent preferences for characteristics of prophylactic treatment in hemophilia
title_short Patient and parent preferences for characteristics of prophylactic treatment in hemophilia
title_sort patient and parent preferences for characteristics of prophylactic treatment in hemophilia
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4664548/
https://www.ncbi.nlm.nih.gov/pubmed/26648701
http://dx.doi.org/10.2147/PPA.S92520
work_keys_str_mv AT furlanroberto patientandparentpreferencesforcharacteristicsofprophylactictreatmentinhemophilia
AT krishnansangeeta patientandparentpreferencesforcharacteristicsofprophylactictreatmentinhemophilia
AT vietrijeffrey patientandparentpreferencesforcharacteristicsofprophylactictreatmentinhemophilia